Calls for papers
-
According to Circassia Pharmaceuticals, the UK has approved the company’s generic fluticasone propionate MDI for the treatment of asthma under the European decentralized procedure. The MAA includes the same three strengths (50µg, 125µg and 250µg… Read more . . .
-
According to the FDA, GlaxoSmithKline has reported that 20 mg and 5 mg dosages of its Imitrex nasal spray for the treatment of migraine headaches will be unavailable until February 2016 due to an API… Read more . . .
-
MannKind Corporation has announced the resignation of Hakan Edstrom, who was the company’s President and CEO, as well as a director. In the wake of the resignation, Alfred Mann has been appointed interim CEO, effective… Read more . . .
-
Novartis today has announced that the Phase 3 FLAME study demonstrated that the Utibron Neohaler (Ultibro Breezhaler) indacaterol/glycopyrronium DPI reduced the rate of COPD exacerbations more effectively than the Advair (Seretide) fluticasone/salmeterol DPI over a… Read more . . .
-
Teva Pharmaceutical Industries has announced top-line results from three Phase 3 clinical studies of its generic fluticasone propionate/salmeterol DPI and a fluticasone propionate monotherapy DPI for the treatment of asthma. The company said that all… Read more . . .
-
The FDA has approved Adapt Pharma’s Narcan naloxone nasal spray for the treatment of opioid overdoses less than four months after the submission of the company’s NDA. Lightlake Therapeutics licensed the intranasal naloxone to Adapt… Read more . . .
-
Turing Pharmaceuticals, which is the subject of several investigations into its pricing strategies, has said that it plans to begin a Phase 1 trial of its TUR-002 intranasal ketamine in the first quarter of 2016.… Read more . . .
-
Consort Medical has announced that it has created a single source supply chain for OINDPs by combining the services of device company Bespak with CDMO Aesica, which Consort acquired in September 2014. Together, the companies… Read more . . .
-
Discovery Laboratories has announced additional data from its Phase 2a trials of Aerosurf aerosolized surfactant for the treatment of respiratory distress syndrome (RDS) in premature infants 29 to 34 week gestational age. that are receiving… Read more . . .
-
Swedish DPI specialist Iconovo has won the 2015 Lund University Innovation System Innovation Prize, which comes with a SEK 150,000 award, the Lund Life Science Incubator has announced. Iconovo’s winning project, titled, “ICOone for inhaled… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA